With our in-house technology platform, scientific expertise in the inner ear, and network of experts, Sensorion can continually develop and optimize its pipeline and market expertise. Consequently, we are poised to expand our pipeline and facilitate other pharmaceutical collaborations.

We select and develop drug candidates from a pool of compounds in late pre-clinical and clinical stage development obtained from partnerships, collaborations and publically available drug libraries.

SENS-401 is currently being evaluated in a Phase 2 clinical trial for SSNHL and Phase 2 ready for Cisplatin-Induced ototoxicity (CIO)

20190603 pipeline


Latest news

  • 21 May 2020

    Sensorion publishes results of General Assembly resolutions. Read

  • 29 Apr 2020

    Sensorion announces it will hold its General Assembly on May 20, 2020 behind closed doors alongside the publication of its 2019 annual financial report. Read

Patient center

Corporate presentation